Jordan
Tuberculosis profile
Population  2013 7.3 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.035 (0–0.4) 0.49 (0–5.5)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.59 (0.27–1) 8.1 (3.7–14)
Incidence  (includes HIV+TB) 0.42 (0.37–0.47) 5.8 (5.1–6.5)
Incidence (HIV+TB only)        
Case detection, all forms (%) 83 (74–94)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 6.3 (2.4–13) 29 (3.7–71)
MDR-TB cases among notified pulmonary
TB cases
12 (5–26) 1 (0–3)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 91   2
Pulmonary, clinically diagnosed 104   0
Extrapulmonary 151   0
       
Total new and relapse 348    
Previously treated, excluding relapses 2    
Total cases notified 350    
Among 326 new and relapse cases:
20 (6%) cases aged under 15 years; male:female ratio: 0.9
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 99 (109%) 0 (0%) 99
Laboratory-confirmed RR-/MDR-TB cases     14
Patients started on MDR-TB treatment     14
TB/HIV 2013 Number (%)
TB patients with known HIV status 348 (99)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 90
Previously treated cases, excluding relapse, registered in 2012 46
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 43
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.2
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 2.9
% Funded domestically 55%
% Funded internationally 19%
% Unfunded 26%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-30 Data: www.who.int/tb/data